A product created by CIC bioGUNE laboratories, that will enable cancer or neurodegenerative disease fighting drugs to be developed, has recently been awarded a patent by the United States Patent and Trademark Office (USPTO).
This product, called TUBEs (Tandem-repeated Ubiquitin Binding Entities), and also known as “ubiquitin trap”, is a system that captures molecules involved in protein degradation. CIC bioGUNE, the Center for Cooperative Research in Biosciences, began its activity 10 years ago and currently holds 4 patents in exploitation out of 9 patent applications.
The new system protected by the US patent enables identification of potential therapeutic targets for multiple pathologies, such as cancer and certain neurodegenerative diseases, caused by a modification in the intercellular protein destruction process.
It is a molecular tool that captures ubiquitin, a protein whose main function is to mark other proteins for destruction, so as to subsequently identify target proteins of therapeutic interest accurately and efficiently.